Cabotegravir and Rilpivirine: A Long-Acting Injectable Antiretroviral Treatment for Human Immunodeficiency Virus

There have been significant developments in effective human immunodeficiency virus treatment since the first antiretroviral was approved. A number of people living with not able to maintain viral suppression on oral therapy. long-acting monthly injectable regimen consisting cabotegravir and rilpivirine has approved for individuals who are virally suppressed. This is a good option those struggle adherence daily or prefer regimen.